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Introduction: Data on heart transplant (HTx) patients and infection with acute respiratory syndrome 
coronavirus 2 (SARS-CoV-2) are very limited. There is significant heterogeneity in the clinical presen-
tation.1 Immunosuppression-related issues are of the main concern because of an increased risk for 
viral replication and superimposed infections. There is no evidence-based recommendation for the 
management of these patients. Some authors suggest modification in immunosuppression, i.e. discon-
tinuation of mycophenolate mofetil (MMF) and calcineurin inhibitor (CNI) reduction in patients with 
more severe clinical presentation.2  
Patients and Methods: This is a case series of 5 HTx recipients from our center who tested positive for 
COVID-19 infection and were treated in different COVID-19 specialized units. 
Results: There were 4 male and one female patients, 62-75 years old. Four of them were symptomatic 
and hospitalized, while one remained self-quarantined at home. The clinical presentation was mild to 
moderate, with symptoms including mild fever, dyspnea, and myalgia. X-ray signs of pneumonia were 
present in 3 patients, but none needed ICU care nor mechanical ventilation. Both a reduction of CNI 
dose with lower target serum concentration and MMF was discontinued in all patients. One patient 
was treated with hydroxychloroquine, one with remdesivir and one with steroid therapy. Antibiotics 
prophylaxis was administered in 2 patients. None of the patients experienced overt graft rejection and 
all patients have successfully recovered (Table 1). 
Conclusion: Lacking any evidence-based recommendation for the treatment of HTx patients infected 
with SARS-CoV-2, we are challenged to modify maintenance immunosuppression carefully balancing 
between the risk of uncontrolled viral replication with a superimposed infection on one side, and the 
increased risk of graft rejection on the other side. Further studies are needed to determine the optimal 
management of COVID-19 infection in these patients.
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Patient 1 Patient 2 Patient 3 Patient 4 Patient 5
Age (years) 63 57 62 75 66
Gender Female Male Male Male Male
Time from HTx (years) 3 3 3 10 5
Imumunosuppressive therapy (mg/day)
Tacrolimus 1.5 2 - 1.5 -
Cyclosporine - - 160 - 160
Mycophenolate mofetil 1500 - 3000 2000 2000
Everolimus - 0.5 - - -
COVID-19 onset 
Presenting symptoms
Cough - + - - -
Shortness of breath + + + - +
Myalgia + + + - +
Anosmia + + - - -
Headache + - - - +
Sinusitis - - - - -
Gastrointestinal symptoms - - - - +
NPS test + + + + +
X-ray pneumonia signs - + + - +
Fever peak (°C) 37.9 38 37.6 36.6 37.8
Hospitalization - + + + +
SpO2 at admission (%) / 90 95 96 96
Worst SpO2 during hospitalization / 90 94 91 96
Laboratory results at admission 
WBC count (cells per 109/l) 4.0 5.5 5.3 2.8 7.5
Hb (g/l) 121 139 139 105 149
Platelets (cells per 109/l) 283 124 192 111 140
Lymphoyte (cells per 109/l) 0.60 1.70 0.55 0.62 /
CRP (mg/l) 0.9 57.4 6.8 0.4 20
Creatinine (umol/l) 107 126 72 136 169
Troponin I (ug/l) / / 4 / /
Treatment and outcomes
Hydroxychloroquine - - - - +
Remdesivir - - + - -
Corticosteroid therapy - + - - -
Discontinuation of mycophenolate 
mofetil
+ + + + +
Antibiotics prophylaxis - + - - +
ICU stay - - - - -
Mechanical ventilation - - - - -
Complications - - - - -
In-hospital length of stay (days) / 5 9 21 11
Outcome Alive Alive Alive Alive Alive
NPS- nasop haryngeal swab test, SpO2 - oxygen saturation, CRP- C-reactive protein, ICU - intensive care unit
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TABLE 1. Main characteristics of the 5 heart transplant patients with COVID-19. 
